Clin2
NCT06750952Possibly a fitNot yet recruiting

Ivonescimab plus chemo for first-line thymic cancer treatment

Relapsed or Metastatic Thymic CancerFirst-line Treatment

Treatments studied

Part of Blood & lymphatic, Cancer clinical trials.

This trial tests a new drug, ivonescimab, combined with chemotherapy for people with thymic cancer that has spread or come back. The goal is to see if this combination can help shrink or control the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
24 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have thymic cancer that has spread or cannot be removed by surgery, and you haven't had treatment for it yet.
  • You are 18 years or older.
  • Your cancer was confirmed as thymic carcinoma (not thymoma) by a biopsy.
  • You are in fairly good health, able to care for yourself (ECOG score 0 or 1).
  • Your major organs (like heart, kidneys, liver, and blood) are working well enough based on blood tests.
  • You have at least one tumor that can be measured on scans.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06980077Recruiting· Phase 2
Ivonescimab for advanced thymic carcinoma

This trial tests a new drug called ivonescimab for thymic carcinoma that has come back or isn't responding to other treatments. It aims to see if this drug can shrink the cancer and help you feel better.

Davis, California
NCT07009925Not yet recruiting· Phase 2
Study of chemotherapy plus ivonescimab for first-line advanced squamous lung cancer

This trial tests a combination of platinum chemotherapy, a paclitaxel nanoparticle formulation, and ivonescimab (an immunotherapy) as the first treatment for people with advanced squamous non-small cell lung cancer that has spread or come back. The goal is to see if this combination helps shrink or control the cancer.

NCT07686575Recruiting
Ivonescimab with chemo for advanced mouth or throat cancer

This trial tests a new drug, ivonescimab, combined with chemotherapy for people with advanced mouth or throat cancer that can be removed with surgery. The goal is to see if the combination helps shrink tumors before surgery.

Guangzhou, Guangdong
NCT06977542Not yet recruiting· Phase 2
Ivonescimab plus chemo before surgery for triple-negative breast cancer

This trial tests whether giving a new immunotherapy drug (ivonescimab) together with standard chemotherapy before surgery can help shrink triple-negative breast cancer and improve outcomes.

NCT06846346Recruiting· Phase 2
Testing Ivonescimab with Chemo for Advanced Stomach Cancer

This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.

Lyon
NCT07094685Recruiting· Phase 2
Ivonescimab before surgery for head and neck cancer

This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.

Ann Arbor, Michigan

Hear when a new First-line Treatment trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.